Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Infuse Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies

NCT01682226
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Lymphoma
Interventions
CliniMACS Fractionation system (Arm A), CliniMACS Fractionation system (Arm B), Haploidentical donor CD34+ cells
Device · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 4 Interventional Results available

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

NCT00331162
View directory record Official record
Conditions
Graft Rejection
Interventions
Alemtuzumab, Anti-Thymocyte Globulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Role of Endothelial Function in SCI CVD Risk

NCT06443151
View directory record Official record
Conditions
Spinal Cord Injuries, Cardiovascular Diseases, Endothelial Dysfunction
Interventions
Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid), venous occlusion plethysmography, Acetylcholine, Sodium Nitroprusside, Ascorbic acid, venous phlebotomy
Procedure · Drug
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 5, 2026, 5:28 PM EDT
Withdrawn Not applicable Interventional

Heparin Versus no Heparin on Duration of Peripherally Inserted Central Catheter (PICC) Patency in Neonates

NCT00879957
View directory record Official record
Conditions
Infant, Premature, Anticoagulants, Thrombosis
Interventions
heparin, No heparin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568
View directory record Official record
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)

NCT01228318
View directory record Official record
Conditions
HIV Infection, Bone Loss, Osteopenia, Osteoporosis
Interventions
Zoledronic acid
Drug
Lead sponsor
Emory University
Other
Eligibility
30 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Results available

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

NCT02659943
View directory record Official record
Conditions
Lymphoma, B-Cell, Lymphoma, Non-hodgkins
Interventions
Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

NCT00782106
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Recombinant human hyaluronidase + immune globulin intravenous
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
16 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting Phase 4 Interventional

Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate

NCT04234971
View directory record Official record
Conditions
Cleft Lip and Palate
Interventions
Intervention group (DBM/BMP), Control group(autologous ICBG)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Years to 15 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Not applicable Interventional Results available

Clinical Comparison of Two Daily Disposable Contact Lenses - Pilot Study 3

NCT04942925
View directory record Official record
Conditions
Myopia, Ametropia
Interventions
Verofilcon A contact lenses, Kalifilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Maitland, Florida • Orlando, Florida • Eden Prairie, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 5, 2026, 5:28 PM EDT
Not listed Not applicable Interventional

An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

NCT04240639
View directory record Official record
Conditions
Neoplasms of the Prostate
Interventions
AuroShell particle infusion
Device
Lead sponsor
Nanospectra Biosciences, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 4 Interventional Results available

Single-shot TAP Block vs Continuous TAP Block

NCT02475031
View directory record Official record
Conditions
Postoperative Pain
Interventions
TAP-C, TAP-S
Device · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

NCT01875601
View directory record Official record
Conditions
Solid Tumors, Brain Tumors, Sarcoma, Pediatric Cancers, Neuroblastoma
Interventions
Recombinant human interleukin-15 (rhIL-15), NK Cell Infusion
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 29 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 4 Interventional

Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery

NCT00508066
View directory record Official record
Conditions
Scoliosis
Interventions
Bupivacaine, Normal Saline
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
8 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting Not applicable Interventional

A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions

NCT03118505
View directory record Official record
Conditions
Multi-Level Degenerative Lumbosacral Spinal Conditions
Interventions
Infuse Bone Graft, Medtronic DBM
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Sacramento, California • Durango, Colorado • Vail, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pathophysiology of Cardiometabolic Risk Factors in African Americans

NCT01122407
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
L-NMMA, Trimethaphan
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 5, 2026, 5:28 PM EDT
Terminated Phase 4 Interventional Results available

A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block

NCT01615939
View directory record Official record
Conditions
Fracture of Foot
Interventions
Bupivacaine, Ropivacaine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting Not applicable Interventional

Use of Tinted Contact Lenses for Concussion-Related Light Sensitivity

NCT07223086
View directory record Official record
Conditions
Concussion, Mild, Photophobia, Contact Lens
Interventions
Narrow band (tinted) contact lenses, broad band (clear) contact lenses
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

One Week Comparison Study of PTH and PTHrP Infusions

NCT01333267
View directory record Official record
Conditions
Osteoporosis, Hypercalcemia of Malignancy, Hyperparathyroidism, Bone Diseases, Endocrine
Interventions
Parathyroid Hormone-related Protein (1-36), parathyroid hormone (1-34), PTH (1-34) and PTHrP (1-36)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 5, 2026, 5:28 PM EDT
Terminated Early Phase 1 Interventional

Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection

NCT02500459
View directory record Official record
Conditions
Brain Tumor, High Grade Glioma
Interventions
topotecan, Cleveland Multiport Catheter
Drug · Device
Lead sponsor
Michael Vogelbaum, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

NCT07211737
View directory record Official record
Conditions
Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 24 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Not applicable Interventional Results available

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

NCT01071512
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 5, 2026, 5:28 PM EDT